Formulation and in Vitro Evaluation of Dasatinib and Hesperidin-Loaded Lipid Nanoformulation for Anticancer Therapy

The goal of this study was to fabricate SLNs loaded with dasatinib and hesperidin for the treatment of chronic myeloid leukemia (CML).

The "central composite design (CCD)" was employed to improve the dasatinib/hesperidin loaded-SLNs during synthesis using a high-shear homogenizer.

Particle diameter index (PDI), average entrapment efficiency (AE), and particle size (nm) were all 0.12% for the improved SLNs. Hence, the polydispersity was enhanced by increasing both the total amount of Compritol and the sonication period. With poloxamer 188 content, the polydispersity index was significantly reduced, and the SLN’s entrapment efficiency (EE) was determined to be 90%. The SLNs’ anticancer activity was tested in-vitro and in-vitro cell viability tests (MTT), and their TEM, SEM, FTIR, DSC, and HPLC analysis was done. Dasatinib and hesperidin-containing 200-nm SLNs are spherical and rounded. The pharmaceuticals and excipients were shown to be compatible using DSC and FTIR analyses. For 48 hours, the drug release from the improved SLN formulation was monitored. Results showed that the medicine had a slow but steady release of its active ingredients; the first four hours saw the release of 28% of the drug, while the next two days saw the release of 75%.

This study developed and tested SLNs loaded with dasatinib and hesperidin, an innovative formulation method that does not include harmful excipients. The aim was to treat chronic myeloid leukemia (CML).